Geriatric nutrition risk index (GNRI) and systemic immunoinflammatory index (SII) might be useful prognostic tools to evaluate recurrence-free survival (RFS) after surgical resection of gastrointestinal stromal tumors (GISTs), according to a study published in Frontiers in Oncology.
The study authors explained, “We retrospectively analyzed the data and we found that RFS was significantly better in the low SII group, 3- and 5-year RFS rates for patients with low SII (≤820) were 86.82% and 83.82% compared with 68.90% and 55.10% for patients with higher SII (>820).”
In addition, the results from the univariate analysis suggested that SII was a risk factor for RFS. Therefore, Lu et al emphasized the promising role of SII as a prognostic factor for GIST.
Furthermore, the authors claimed, “We were the first to demonstrate that GNRI was the risk factor for patients with GIST.” Their results showed that patients with a high GNRI (>98.3) had 3- and 5-year RFS rates of 93.95% and 91.96%, respectively, while patients with a low GNRI had lower 3- and 5-year RFS rates (66.99% and 60.19%, respectively).
Read more about GIST prognosis
This study included 160 patients (mean age, 60±12 years; 56.2% male) who underwent radical resection of GIST and received no adjuvant tyrosine kinase inhibitor therapy. Most patients were classified into either low- (33.1%) or high-risk (30.0%) groups according to the modified National Institutes of Health GIST risk classification.
SII is calculated based on peripheral blood platelet, neutrophil, and lymphocyte counts. Patients with a high SII are usually more prone to inflammation and a weakened immune response.
GNRI is an adaptation of the nutritional risk index (NRI) developed for the specific evaluation of elderly individuals. Instead of using previous weight measurements, GNRI is calculated based on ideal body weight.
Lu Z, Li R, Cao X, et al. Assessment of systemic inflammation and nutritional indicators in predicting recurrence-free survival after surgical resection of gastrointestinal stromal tumors. Front Oncol. 2021;11:710191. doi:10.3389/fonc.2021.710191